Kinoxis Therapeutics
Melbourne, Australia, 8 June 2023
Kinoxis awarded new US grant funding to support clinical development of KNX100 for opioid use disorder.
Melbourne, Australia, 5 May 2023
Kinoxis Therapeutics partners with Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms.
Melbourne, Australia, 22 December 2020
Kinoxis Completes $5M Financing Round and Advances Lead Program Through Key Toxicology Studies
Melbourne, Australia, 30 September 2019
Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal
Melbourne, Australia, 15 February 2018
Kinoxis Therapeutics Launched to Develop Novel Anti-addiction Drugs